Stoke Therapeutics, Inc.
(STOK - NASDAQ)
33,71 USD
📋 Profilo Aziendale

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.

|